GTS Securities’s Citius Pharmaceuticals CTXR Stock Holding History

GTS Securities’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-403	Closed	-$6.89K	–	4089
2023 Q3	$6.89K	Buy	+403	New	+$9.58K	﹤0.01%	3828

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

GTS Securities's CTXR Position: Q4 2023 in Review

GTS Securities sold out of Citius Pharmaceuticals (CTXR) in Q4 2023, closing a stake of 403 shares — an estimated $6.89K sold.

GTS Securities first reported a position in CTXR in Q3 2023 and held it in 1 quarter. The position peaked at $6.89K in Q3 2023. 74 funds tracked by Wall St. Rank hold CTXR as of Q4 2023.

GTS Securities reported no remaining Citius Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 403 Citius Pharmaceuticals shares in Q4 2023, an estimated $6.89K.
GTS Securities first reported a position in Citius Pharmaceuticals in Q3 2023 and held it in 1 quarter.
GTS Securities's Citius Pharmaceuticals position peaked at $6.89K in Q3 2023.
74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.